MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
*Driving Forces: BioPharmaceuticals _ Biotechnology, Genomics, Genetics, Bioinformatics, Biomanufacturing & Personalized Medicine
*Biotechnology: Key Issues
*Key Terms: Biotechnology
Bacteria
Parents
*Key Terms: Biotechnology
BioTechnology
Infectious Disease
Children
- Cell Culture Expression Systems Including Bacterial, Yeast, Insect, Avian, and Mammalian Cells
*Clarametyx Biosciences is combating persistent and recalcitrant infections through a technology platform targeting the biofilm—a protective layer around bacteria—to enable a more effective immune response or antibiotic intervention.
*Clinical programmes target: Duchenne muscular dystrophy, a fatal genetic muscle wasting disease, and the infectious disease caused by the bacteria C. difficile.
*Discovery, development, and commercialization of treatments to fight bacterial, fungal and viral infection
*Including antibiotic-resistant strains of bacteria, as well as viruses, fungi and spores.
*More than 45 companies have licensed Xoma technology for making proteins in bacteria
*Per the company, cell-free technology has the potential to overcome many of the significant limitations associated with using whole mammalian and bacterial cells for making protein-based biologics.
*The Company is building a pipeline of immune-enabling therapies and vaccines for life-threatening bacterial infections associated with biofilms.
*The company specializes in using genetic engineering to produce bacteria with industrial applications.
2010: Confocal Laser Endomicroscopy for Live Visualization of GI Bacteria (2010)
2010: PMX-30063 is a small molecule that mimics the mechanism of action of human host defense proteins, a mechanism that is distinct from currently approved antibiotic drugs and is intended to make bacterial resistance unlikely to develop.
2011: Five Novel Antimicrobial Technologies for Battling Bacteria Qmed (2011)
2011: New Type of Drug Kills Antibiotic-Resistant Bacteria (2011)
2011: The Next Step?-DARPA wants to use siRNAs to treat bacterial infections in US troops (2011)
2013: Diabetes-focused Microbiome Therapeutics raises $1.3M to test meds that alter gut bacteria_medcitynews (2013)
2014: 'Nightmare bacteria' fighter Achaogen sets IPO range
2014: DTRA - RF - INovel Mechanism Based Multiple Drug Resistance Broad Spectrum Anti-Threat Bacterial Pathogens Antibiotics - Response Date: Mar 05, 2014
2014: DTRA_Novel Mechanism Based Multiple Drug Resistance Broad Spectrum Anti-Threat Bacterial Pathogens Antibiotics:(Sources Sought): Mar 26, 2014
2014: Most current point-of-care tests for viruses and bacteria are based on antibody technology, the next frontier within this fast-diagnosis market is a nucleic acid-based test like the one Lucigen is working on.
2014: NIH-RFA-AI-14-019: Partnerships for Diagnostics to Address Antimicrobial Resistance of Select Bacterial Pathogens (R01)=$4,500,000 - Letter of Intent: May 19, 2014
2017: CDC_Comparison of Methods for Detecting Recombination in Bacterial Whole Genome Sequences
2017: MTEC_Electroceutical Technology Against Bacterial Drug Resistance
2017: Paratek is developing omadacycline in adult communiy acquired bacterial pneumonia
2019: BiomX nets $32M to engineer bacteria-killing viruses for IBD and acne
2019: MTEC_Small molecule antibiotic drug development for Combating Antibiotic Resistant Bacteria(CARB)”_mtec-sc.org
2019: This biotech aims to cure Alzheimer's by killing gum-disease bacteria
2020: Clarametyx Biosciences Awarded up to $14.2 Million From CARB-X to Accelerate Novel Immune-Enabling Technology to Combat Persistent Bacterial Infections
2020: CMS extends add-on payment to T2 Bio's bacterial panel
2020: DARE had kicked off its pivotal trial for the candidate in patients with bacterial vaginosis (BV)
2021: Biomaterial-Based Vaccine Against Bacterial Infection
2021: Engineered Surfaces Reduce Bacterial Attachment and Growth
2021: Hydrogel Wound Treatment Kills Antibiotic Resistant Bacteria
2021: Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) shares closed the week up 17% to $9.60 following news the FDA approved its supplemental New Drug Application (sNDA) for the oral-only dosing regimen of NUZYRA for the treatment of adults with Community-Acquired Bacterial Pneumonia (CABP).
3. Novel diagnostic platforms for rapid high throughput diagnostics of viral and bacterial infections
A prototype of this enzyme inhibitor showed that blocking the bacterial repair abilities of the enzyme improves the effects of antibiotics such as flouroquinolone and penicillin.
a. Viral, Toxin and Bacterial Studies:
Advantages over available alternatives include speed, cost, and test of human (rather that rodent or bacterial) cells
Against advanced biological threats, including genetically modified intracellular bacterial pathogens and hemorrhagic fever viru
Aims to commercialize a new and more effective therapy to treat antibiotic-resistant bacterial infections.(2011)
AvidBiotics develops novel, non-antibody proteins as targeted therapeutics against bacteria, viral infections and cancer.
Bacteria grows on the membrane, which is then transferred to a staining plate, and allows bacterial micro colonies to become visible after about five minutes
bacterial byproducts in anaerobic infections
Bacterial Pathogenesis Study Section, NIH
Bacterial Threats
Bacterial, Cancer or Other Cells
BacterioScan is commercializing electro-optic instruments and disposables for rapidly detecting and measuring the concentration and growth of bacteria in fluids for research and medical diagnostic applications
BARDA_CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator)
BioMEMS Sensor System for Bacterial Infection Detection
Can deliver specific phages for human and animal health and food safety applications that are timely, cost effective, better for the environment and highly effective on exposed bacteria.
Cempra develops medicines to meet the increasing need for treating drug-resistant bacterial infections in the community and hosp
Clinical-stage biotechnology company focused on small molecules for the treatment of severe bacterial infections, sepsis, necrotizing soft tissue infections and intra-abdominal infections
Cold atmospheric plasmas are partially ionized gases which very efficiently inactivate bacteria, fungi, viruses, spores and odour molecules.
Commercialize a bacterial detection technology licensed from the Colorado School of Mines
Continuous Detection System to Monitor Environmental Air for Bacterial Contaminations by Jan Sinnige on Jul 29, 2011-Internet Journal Of Emerging Medical Technologies
CUBICIN(R) (daptomycin for injection), CXA-201, for Gram-negative bacterial infections, including multi-drug resistant Pseudomonas aeruginosa, CB-183,315, a potent, oral, bactericidal lipopeptide, for Clostridium difficile-associated diarrhea (CDAD)
Cytophage is a Canadian private corporation that has an innovative template technology that uses synthetic biology to create tailor-made bacteriophage products that can bind to and kill bacterial cells.
Delivering fecal matter in oral medication form as a treatment for guts teeming with C difficile bacteria sounds like an extraordinary remedy.
develop a unique bacterial anti-tumor agent (an engineered avirulent guanine-dependent mutant of Yersinia pestis)
Developing a battery-powered, pen-like device that uses cold plasma technology to sterilize and heal wounds, including those infected with drug-resistant bacteria like MRSA.
Developing a point-of-care, hand-held diagnostic device to screen a fluid sample for specific pathogenic bacteria.
Developing novel anti-bacterial bioconjugate vaccines recombinantly using E. coli as a host – no longer dependent on conventional complex synthetic chemistry for conjugate vaccine production.
Developing ultra-precise antibiotics to target harmful bacteria and sparing beneficial ones
Development of its nitric oxide technology into a bacteria-fighting tool.
Develops diagnostics kits for bacteria and other microorganisms that it says are several times faster than traditional methods of detection
DHA_Industry Day 2019_Key_Note_Speaker_Brief
Discovers and develops small molecule inhibitors of bacterial resistance
Discovery, development and commercialization of therapies for the treatment of inflammatory diseases and bacterial infections
Einterz says the bandage has two active ingredients that kill bacteria by dehydrating it — a different approach from anything else on the market.
First tenant at University of Michigan's incubator pursuing device to speed bacterial infection tests (2011)
First vaccine shown to provide protection against pathogens from two kingdoms: fungi and bacteria.
For use against resistant strains of streptococcus, staphylococcus and other bacterial and fungal human pathogens
Genentech's first r&d project was to determine whether human proteins could be produced in a bacteria cell
Glycobia employs proprietary BUG™ (bottom-up glycoengineering) technology to design bacteria that produce novel and enhanced biotherapeutics
Has been a leading innovator of tests for bacterial, viral, and parasitic diseases.
HJF and Altor Bioscience Corp., Miramar, Fla., have been assigned a patent (7,884,198) developed by 4 co-inventors for "polynucleotides encoding humanized and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria."
It identifies the bacteria if it can or counts the bacteria and then does an antibiotic sensitivity test on them within an hour.
Lipopolysaccharide (LPS) is a major component of the bacterial outer walls that can cause profound and diverse effects in mammal
Makes a product that detects bacterial contamination in a blood supply
Malabsorption, bacterial overgrowth of the small bowel,
NanoLogix develops diagnostic kits for a wide variety of bacteria and microorganisms, which includes salmonella, E. coli, listeria, staph, anthrax, spores and mold.
Nanotechnology based delivery system for a bacterial meningitis B vaccine
New mouthwash targeting harmful bacteria may render tooth decay a thing of the past (2011)
Novome Biotechnologies is engineering bacteria from the human gut to treat diseases.
Novome is utilizing its proprietary GEMMs platform in its lead preclinical program in hyperoxaluria, which is focused on the development of a therapeutic strain of bacteria that degrades oxalate to prevent the formation of kidney stones.
NUZYRA (omadacycline) is a broad spectrum, novel antibiotic with both once-daily intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections
Offers long lasting protection from bacteria (e.g., pneumonia) and viruses (e.g., HIV) without promoting the emergence of microb
Patented technology creates phages that target specific bacteria, to treat virtually any bacterial infection or disease.
Peptic ulcer is a disorder of the upper gastrointestinal tract that results when gastric acid, bacteria, drugs, or other assault
Phosphorylated and Branched DPD Analogs as Quorum Sensing Inhibitors in Bacteria-University of Maryland
Provides hospital and laboratory customers with a simpler, cheaper option to test samples for certain types of bacteria
Removal of significant amounts of biofilm, prior to bronchoscopy will limit the bacteria carried into the lungs by bronchoscopes
Reported a new approach for preparing arrays of bacterial cells that will eventually be incorporated into biosensors.
Sensei Bio (NASDAQ: SNSE) is a clinical-stage oncology company developing a novel, personalized cancer vaccine platform based on bacteriophages, small viruses that typically infect bacteria.
Stadius Biopharma is developing proprietary fully human antibody therapeutics and a stem cell antibody delivery system for the prophylaxis and treatment of patients with resistant and potentially life threatening bacterial, fungal, and viral infections.
Technique for Detecting and Differentiating Bacterial Pathogens
The Company has developed the first-ever platform for controlled colonization of the gut with engineered bacteria, enabling first-in-class living therapeutics: Genetically Engineered Microbial Medicines (GEMMs).
The company is developing compounds that inhibit the bacterial enzyme RecA.
The company's Harmonic Cold Plasma Technology can eradicate antibiotic resistant bacteria, fungi, and viruses related to infections in wounds, burns, and surgical sites
The Company’s Genome Sequence Scanning technology can simultaneously identify thousands of bacterial strains in a single test in three hours.
The company’s tests can identify the presence and type of infection (viral or bacterial), and the risk of severe disease, including severe COVID-19, to enable physicians to make more informed decisions.
The contract is for Phase 1 research into the development of the sampling platform, which will be used to identify hazards such as toxins, viruses, vegetative bacteria and spores in matrices including blood, soil, food and water.
The detection platforms covered by this IP include simple consumer grade sensors for bacterial monitoring, rapid enzyme-linked (
The device contains samples of antibiotics and electronic sensors within the device monitor the growth of bacteria from a sample under the influence of those antibiotics.
The mAbLogixTM system produces human monoclonal antibodies against any target including bacterial and viral antigens as well as tumor antigens and human auto-antigens.
The mist discourages bacteria and carries the low-frequency sound waves, which stimulate cell growth and regeneration.
The other vaccine, Prevnar, licensed to Wyeth Pharmaceuticals, prevents pneumococcal bacteria that can cause meningitis.
Therapeutics for combating the increasing bacterial resistance to antibiotics
This enzyme is a key factor in bacterial DNA repair and the development of antibiotic resistance.
This technology kills pests (insects), eliminates dangerous pathogens/ bacteria, and extends shelf-life without adding any chemicals or residue.
This will make it possible for ABOID to detect and identify microorganisms in minutes rather than hours by having access to a database of 4,500 unique genomes of bacteria, viruses, and fungi.
Three lead compounds in development—two of which are topically administered dermatology drugs, while a third is an antibiotic that circulates through the bloodstream to fight Gram-negative bacteria
Transgenic Approaches Using bacterial artificial chromosome (BAC) Clones to ID Genes for Phenotypes-LLVAMC
Unlocks the potential of nature’s elegant and harmless anti-bacterial solution - phages.
Use of Lantibiotics in Environmental Decontamination as Inhibitors of Food-Borne Pathogens and to Fight New Strains of Bacteria-University of Maryland
Using E. coli bacteria to induce cyathin A3 production from the fungus Cyathus helanae-George Mason Intellectual Properties, Inc.
VaxInnate is developing a recombinant influenza vaccine technology based on combining influenza and bacteria proteins to stimulate strong immune response to protect against the flu/H1N1.
Verax makes the Platelet PGD Test, an FDA-cleared diagnostic that can detect bacterial contamination in blood platelets hours before transfusion
Jumps
Multiomics